EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Galectin-9—An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy

Anastasia Iris Karkempetzaki, Tobias Schatton, Steven R Barthel

International Journal of Molecular Sciences · 19.08.2025 · 26 (16) · 7998

DOI: 10.3390/ijms26167998 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.08.2025. Verfasst von Anastasia Iris Karkempetzaki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Galectins, Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 248 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIH/NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Galectin-9 (Gal-9, LGALS9) is a member of the family of carbohydrate-binding lectins known as galectins. Galectins bind a diverse repertoire of galactose-bearing glycoprotein receptors expressed across multiple cell types. These interactions elicit a broad spectrum of pleiotropic effects important in both normal physiology and disease pathogenesis. Gal-9 contains two separate carbohydrate recognition domains with overlapping yet also divergent binding affinities for distinct glycostructures. This tandem repeat motif enables fine-tuning of its various biological functions. Additional control of Gal-9 activity is provided via multiple gene variants, protein isoforms, tissue distribution, and cell type-associated glycoprotein binding profiles. Within the tumor microenvironment, Gal-9 interacts with immune, non-immune, and cancer cells to influence malignant progression. Its binding of the premier immune checkpoint glycoreceptors, T-cell immunoglobulin and mucin-domain-containing-3 (TIM-3) and programmed cell death protein 1 (PD-1), places Gal-9 apart as a burgeoning target for immunotherapy. In this review, we delve into important aspects of Gal-9 immunobiology in tumorigenesis, including glycobiological and lineage-dependent functions. We further examine Gal-9 as a promising new glyco-immune checkpoint target for cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GalectinsNeoplasmsImmune Checkpoint InhibitorsHumansAnimalsTumor MicroenvironmentImmunotherapy

Stichwörter der Autor:innen

Galectin-9PD-1TIM-3cancergalectinsglycobiologyimmune checkpointimmunotherapy

Substanzen

GalectinsLGALS9 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Program of Glyco-Immunology and Oncology (PGIO), Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • School of Medicine, University of Crete, 71003 Heraklion, Greece.
  • Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NIH/NCI

Zitieren

APA

Karkempetzaki, A. I., Schatton, T., & Barthel, S. R. (2025). Galectin-9—An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy. International Journal of Molecular Sciences, 26(16), 7998. https://doi.org/10.3390/ijms26167998

Vancouver

Karkempetzaki AI, Schatton T, Barthel SR. Galectin-9—An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy. International Journal of Molecular Sciences. 2025;26(16):7998. doi:10.3390/ijms26167998

BibTeX
@article{Karkempetzaki2025,
  author = {Karkempetzaki, Anastasia Iris and Schatton, Tobias and Barthel, Steven R},
  title = {Galectin-9—An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {16},
  pages = {7998},
  doi = {10.3390/ijms26167998}
}
Kostenlos starten →